Sunshine Guojian Pharmaceutical

688336 · SSE STAR Market

Public Market Listing

688336SSE STAR Market

SSE STAR Market primary exchange listing

Live quotes, historical charts, and market capitalization for Sunshine Guojian Pharmaceutical are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
IL-17AMonoclonal antibody
Psoriasis
Phase 3
IL-4R-alphaMonoclonal antibody
Atopic Dermatitis
Phase 2
TL1ABiologic (subtype unspecified)
Inflammatory Bowel Disease
Ulcerative Colitis

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (1)
Amdokitug (Yisaituo)Phase 3Ankylosing Spondylitis
Est. primary completion 2027-01-14 · NCT07261644 · CT.gov ↗
What to watch
September 2027 (1)
SSGJ-611Phase 3Dermatitis, Atopic
Est. primary completion 2027-09 · NCT07767253 · CT.gov ↗
What to watch
2028 (2)
April 2028 (1)
Amdokitug (Yisaituo)Phase 3Axial Spondyloarthritis, Non-Radiographic
Est. primary completion 2028-04-19 · NCT07349329 · CT.gov ↗
What to watch
September 2028 (1)
SSGJ-611Phase 3Pulmonary Disease, Chronic Obstructive (COPD)
Est. primary completion 2028-09 · NCT07039669 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
SSGJ-627Phase 2Ulcerative Colitis (UC)
Est. primary completion 2029-02-28 · NCT07507513 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 August 2026Topline resultSSGJ-608Pivotal Phase 3 NCT05536726 met both co-primary endpoints (PASI75 and sPGA 0/1 at week 12)
Sunshine Guojian Pharmaceutical · Source ↗
February 2026Filing acceptedSSGJ-611China marketing application for 611 (anti-IL-4Rα) in adult atopic dermatitis accepted for review
CN, NMPA · Sunshine Guojian Pharmaceutical (3SBio) · Source ↗

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$585M—$243M—report ↗